Kan Yonemori

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

Toshihiko Doi, Kohei Shitara, Yoichi Naito et al. · The Lancet Oncology · 2017 · 501 citations

Medicine, Oncology, Pharmacology +17

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

Éric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 405 citations · Full text

Medicine, Gynecology, Oncology +13

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

Aditya Bardia, Xichun Hu, Rebecca Dent et al. · New England Journal of Medicine · 2024 · 393 citations

Medicine, Oncology, Pharmacotherapy +17

Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study

Kuniko Sunami, Hitoshi Ichikawa, Takashi Kubo et al. · Cancer Science · 2019 · 377 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer

Makiko Ono, Hitoshi Tsuda, Chikako Shimizu et al. · Breast Cancer Research and Treatment · 2011 · 306 citations

Medicine, Immunology, Oncology +15